Additionally, BCL2 amplicon loss was detected in the HBL-2 mantle cell lymphoma line and the VAL double-hit/HGBL lymphoma line [71], although this is unlikely to be a major venetoclax resistance mechanism in DLBCL since BCL2 amplification in DLBCL occurs infrequently [72]. The gene discussed is BCL2; the disease is lymphoma.